Preventing stroke is an important goal in the clinical management of patients with atrial fibrillation (AF). While oral anticoagulation (OAC) reduces the risk of ischemic stroke and systemic embolism, patients with AF may still have ischemic strokes despite taking OACs. Additionally, there is a growing population of AF patients who are unable to take anticoagulants. In this issue of Cardiovascular Revascularization Medicine , Yodfat et al. report the feasibility, safety, and efficacy of a novel common carotid artery (CCA) coil filter (Vine™; Javelin Medical Ltd., Israel) implant in pre-clinical testing.